The Handbook of Biological Therapy

by Kirkham, Bruce; Kavanaugh, Arthur; Plevy, Scott Eric; Barker, Jonathan

• ISBN13: 9780199208166
• ISBN10: 0199208166
• Edition: 1st
• Format: Paperback
• Copyright: 2009-01-15
• Publisher: Oxford University Press

Summary

Tumor Necrosis Factor (TNF) blocking therapy has recently been introduced as an important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and psoriatic arthritis. This class of drugs, currently comprised of three different agents, is being increasingly used for these around the world. Intensive clinical research is also defining new areas in which these drugs will be used in the future. These new indications for TNF-blocking therapy will increase the number of physicians using this class of drug. This guide provides a comprehensive distillation of the clinical experience with these drugs combined with the diverse available databases to provide practical information about the use of these drugs in daily practice. Much of the literature currently available has come from the clinical trial setting with an academic emphasis. This book is rigorously practical and is the guide that every physician including all rheumatologists, and gastroenterologists and dermatologists who treat patients with this class of drugs, will want to have on hand to answer their questions that arise every day.

Author Biography

Dr. Bruce Kirkham is currently Clinical Lead in Rheumatology/Lupus at Guy's & St. Thomas' Hospital Trust, London. His clinical research interests focus on optimising the use of drugs for the treatment of inflammatory arthritis. Arthur Kavanaugh, MD, is a Professor of Medicine at the University of California, San Diego (UCSD) School of Medicine and Director of the Center for Innovative Therapy in the UCSD Division of Rheumatology, Allergy, and Immunology. He is also a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Rheumatology (ACR). Scott Plevy, MD, is an Associate Professor of Medicine, Microbiology and Immunology at the University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology. He is the Director of the University of North Carolina FOCIS Center of Excellence. Jonathan Barker has been Academic Head of St John's Institute of Dermatology since 2002. He is co-director of the Skin Therapy Research Unit and head of the Psoriasis Service at St John's Institute of Dermatology. His research interests focus on inflammatory skin diseases, particularly psoriasis.

Table of Contents

Foreword	p. v
Preface	p. vii
TNF - tumour necrosis factor ¿	p. xi
Mode of action of anti - TNF	p. xii
TNF-blocking drugs in clinical use	p. xiii
TNF-blocking drugs not in clinical use	p. xiv
TNF-blocker safety
Increased risk of infection	p. 2
Tuberculosis	p. 3
Opportunistic infections	p. 7
Injection-site reactions	p. 7
Allergic, hypersensitivity reactions, anaphylactic responses	p. 7
Psoriasis	p. 8
Infusion reactions (infliximab)	p. 8
Malignancy and lymphoproliferative conditions	p. 9
Drug-induced lupus-like reactions	p. 12
Anti-drug antibodies (immunogenicity)	p. 12
Congestive heart failure	p. 13
Neurological	p. 14
Hepatobiliary	p. 15
Use in pregnancy	p. 16
Lactation	p. 17
Respiratory	p. 17
Vaccinations	p. 17
Use of TNF-blockers with other medications	p. 18
Haematological	p. 18
Postmarketing safety experience in Crohn's disease	p. 18
Rheumatology
Rheumatoid arthritis	p. 27
Other rheumatological conditions	p. 34
TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis	p. 38
Ankylosing spondylitis	p. 38
Psoriatic arthritis	p. 44
Adalimumab (Humira)	p. 48
Etanercept (Enbrel)	p. 57
Infliximab (Remicade)	p. 68
Certolizumab pegol (Cimzia)	p. 79
Abatacept (Orencia)	p. 81
Anakinra (Kineret)	p. 89
B-cell depletion: Rituximab (Rituxan® [USA], Mab Thera® [Europe, Asia, South America])	p. 93
Dermatology
Psoriasis	p. 98
Approaches to management	p. 99
Assessing disease severity	p. 100
Important differences between psoriasis and rheumatoid arthritis	p. 101
Biological therapy for psoriasis	p. 101
Etanercept (Enbrel)	p. 103
Infliximab (Remicade)	p. 106
Adalimumab (Humira)	p. 110
Efalizumab (Raptiva)	p. 113
Alefacept (Amevive)	p. 118
Gastroenterology
Biological therapy in inflammatory bowel disease and Crohn's disease	p. 122
Adalimumab (Humira)	p. 131
Infliximab (Remicade)	p. 135
Natalizumab (Tysabri)	p. 143
Certolizumab pegol (Cimzia)	p. 148
Index	p. 151
Table of Contents provided by Ingram. All Rights Reserved.